CSF_PsA_Highlights Brochure_ACR2022
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ACR 2022<br />
Congress Preview<br />
<strong>PsA</strong><br />
Steering Committee Introduction<br />
Dear Colleagues,<br />
Welcome to my selection of the ACR abstracts for <strong>PsA</strong>.<br />
In this brochure you will find 37 abstracts that I believe are of particular interest. We have additionally highlighted 12 of<br />
these abstracts as my ‘top picks’ which, are not to be missed.<br />
Day 1 starts off with a fantastic collection of posters we think you will enjoy, with the presentation of the latest data on<br />
risankizumab from the KEE<strong>PsA</strong>KE 1 & 2 trials (308) first on the list. A host of additional posters featuring data on a number<br />
of clinical interventions are also present during the Spondyloarthritis Including <strong>PsA</strong> – Diagnosis, Manifestations, and<br />
Outcomes Poster I session, including changes in disease activity due to ixekizumab (380), an investigation into the skin<br />
response following guselkumab withdrawal (391), and a discussion on the impact of BMI on secukinumab therapy (395).<br />
There are a great many recommended posters to be seen on Day 2 of ACR as well, in particular those being showcased<br />
in the Abstracts: Spondyloarthritis Including <strong>PsA</strong> – Treatment II: <strong>PsA</strong> session. This includes the latest data on izokibep<br />
presented by Steering Committee member Frank Behrens (1597), as well as the latest safety and efficacy data for<br />
deucravacitinib (1598), and phase III data for bimekizumab (1599). Spondyloarthritis Including <strong>PsA</strong> – Treatment Poster<br />
II: Mixed represents another fantastic poster session we recommend you attend. In particular we would suggest two<br />
posters; the first of which looks at the long-term safety of ixekizumab in PsO, <strong>PsA</strong>, and axSpA (1042), the other looking at<br />
the impact of secukinumab on uveitis in <strong>PsA</strong> and axSpA (1043).<br />
Finally, Day 3 plays host to a particularly inspiring session: Spondyloarthritis Including <strong>PsA</strong> – Treatment Poster III: <strong>PsA</strong>.<br />
This includes a host of novel guselkumab related posters (1850, 2127, 2128 & 2139), as well as the latest phase II data<br />
for deucravacitinib in <strong>PsA</strong> (2133). I also present the latest 2-year data from the SELECT-<strong>PsA</strong> 2 trial (2146), and Lars Erik<br />
presents yet more findings from the KEE<strong>PsA</strong>KE 1 and KEE<strong>PsA</strong>KE 2 trials with risankizumab in <strong>PsA</strong> (2145).<br />
As always thank you for your continued support,<br />
Kind regards<br />
Professor Philip Mease<br />
SPONSORSHIP AND UNRESTRICTED EDUCATIONAL GRANTS FROM<br />
Register for FREE content at www.cytokinesignalling.com<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE<br />
Follow us at:<br />
Cytokine Signalling Forum
Key Presentations<br />
Saturday, 12 November 2022<br />
13:00–<br />
15:00<br />
0308<br />
13:00–<br />
15:00<br />
0380<br />
0391<br />
0395<br />
POSTER SESSION<br />
RA – TREATMENT POSTER I<br />
Risankizumab (RZB) Demonstrates Long-Term<br />
Efficacy Across Subgroups in Patients with Active<br />
Psoriatic Arthritis (<strong>PsA</strong>): A Post Hoc, Integrated<br />
Analysis from the Phase 3 (KEE<strong>PsA</strong>KE 1 and<br />
KEE<strong>PsA</strong>KE 2) Studies<br />
Joseph Merola<br />
POSTER SESSION<br />
SPONDYLOARTHRITIS INCLUDING PSA<br />
– DIAGNOSIS, MANIFESTATIONS, AND<br />
OUTCOMES POSTER I<br />
Changes in Disease Activity and Patient-Reported<br />
Outcomes in Psoriatic Arthritis Patients Treated with<br />
Ixekizumab in a Real-World US Cohort<br />
William Tillett<br />
Dynamics of Nail Psoriasis with Guselkumab<br />
Treatment and Withdrawal in Association with Skin<br />
Response and Patient-reported Outcomes Based on a<br />
post Hoc Analysis of Clinical Trial Data<br />
William Tillett<br />
How Does Body Mass Index Affect Secukinumab<br />
Treatment Outcomes and Safety in Patients with<br />
Psoriatic Arthritis? – Real World Data from a German<br />
Observational Study<br />
Uta Kiltz<br />
Sunday, 13 November 2022<br />
09:00–<br />
10:30<br />
1006<br />
09:00–<br />
10:30<br />
1035<br />
1036<br />
1040<br />
1042<br />
1043<br />
13:00–<br />
15:00<br />
1493<br />
POSTER SESSION<br />
SPONDYLOARTHRITIS INCLUDING PSA<br />
– DIAGNOSIS, MANIFESTATIONS, AND<br />
OUTCOMES POSTER II<br />
Impact of Uric Acid Levels on Clinical and<br />
Radiographic Characteristics in Psoriatic Arthritis<br />
and Response to Secukinumab: A Pooled “Post Hoc”<br />
Analysis from Five Phase 3 Studies<br />
Renaud Felten<br />
POSTER SESSION<br />
SPONDYLOARTHRITIS INCLUDING PSA –<br />
TREATMENT POSTER II: MIXED<br />
Efficacy of Guselkumab in Three Cohorts of Biologic-<br />
Naïve <strong>PsA</strong> Patients with Axial Involvement Defined<br />
Based on Imaging and Machine-Learning Criteria:<br />
Pooled Analysis of Two Phase 3 Studies<br />
Philip J Mease<br />
Efficacy and Safety of Tofacitinib in Patients with<br />
Psoriatic Arthritis or Ankylosing Spondylitis by History<br />
of Cigarette Smoking<br />
Alexis Ogdie<br />
Impact of Weight and Sex on Long-term Persistence<br />
to Secukinumab Treatment in Patients with Active<br />
Psoriatic Arthritis or Ankylosing Spondylitis<br />
Uta Kiltz<br />
Long-term Safety of Ixekizumab in Adult Patients<br />
with Psoriasis, Psoriatic Arthritis, and Axial<br />
Spondyloarthritis<br />
Atul Deodhar<br />
Uveitis in Patients with Axial Spondyloarthritis or<br />
Psoriatic Arthritis: Baseline Characteristics and<br />
Incidence Rates During Secukinumab and Placebo<br />
Comparative Phase: A Post Hoc Analysis<br />
Jan Brandt-Juergens<br />
POSTER SESSION<br />
SPONDYLOARTHRITIS INCLUDING PSA<br />
– DIAGNOSIS, MANIFESTATIONS, AND<br />
OUTCOMES POSTER III<br />
Impact of Delay of Treatment with Disease Modifying<br />
Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis:<br />
Lessons from the CorEvitas <strong>PsA</strong>/SpA Registry<br />
Philip J Mease
Chair’s Picks<br />
1504<br />
1509<br />
15:00–<br />
15:10<br />
1597<br />
15:15–<br />
15:25<br />
1598<br />
15:30–<br />
15:40<br />
1599<br />
Efficacy of Risankizumab in the Treatment of <strong>PsA</strong><br />
Patients with Limited and Extensive Joint Involvement<br />
Lars Erik Kristensen<br />
Patient Clusters Identified by Machine Learning<br />
from a Pooled Analysis of the Clinical Development<br />
Program of Secukinumab in Psoriatic Arthritis,<br />
Ankylosing Spondylitis and Psoriatic Arthritis with<br />
Axial Manifestations<br />
Xenofon Baraliakos<br />
ORAL SESSION<br />
ABSTRACTS: SPONDYLOARTHRITIS<br />
INCLUDING PSA – TREATMENT II: PSA<br />
Achievement of Different Treatment Targets with<br />
Izokibep Demonstrates Efficacy Benefits in Patients<br />
with Active Psoriatic Arthritis: Results from a 16-Week<br />
Randomized, Placebo-Controlled Phase 2 Clinical Trial<br />
Frank Behrens<br />
ORAL SESSION<br />
ABSTRACTS: SPONDYLOARTHRITIS<br />
INCLUDING PSA – TREATMENT II: PSA<br />
Safety and Efficacy of Deucravacitinib, an Oral,<br />
Selective Tyrosine Kinase 2 Inhibitor, in Patients<br />
with Psoriatic Arthritis: 52-Week Results from a<br />
Randomized Phase 2 Trial<br />
Philip Mease<br />
ORAL SESSION<br />
ABSTRACTS: SPONDYLOARTHRITIS<br />
INCLUDING PSA – TREATMENT II: PSA<br />
Bimekizumab Treatment in Patients with Active<br />
Psoriatic Arthritis and Inadequate Response to Tumor<br />
Necrosis Factor Inhibitors: 16-Week Efficacy and<br />
Safety from a Phase 3, Randomized, Double-Blind,<br />
Placebo-Controlled Study<br />
Joseph Merola<br />
Monday, 14 November 2022<br />
13:00–<br />
15:00<br />
1850<br />
13:00–<br />
15:00<br />
2127<br />
2128<br />
2129<br />
2131<br />
2132<br />
2133<br />
2134<br />
POSTER SESSION<br />
MISCELLANEOUS RHEUMATIC AND<br />
INFLAMMATORY DISEASES POSTER III<br />
Guselkumab Provides Sustained Improvements in<br />
Health-Related Quality of Life in Patients with Active<br />
Psoriatic Arthritis Through 2 Years of DISCOVER-2<br />
Jeffery Curtis<br />
POSTER SESSION<br />
SPONDYLOARTHRITIS INCLUDING PSA –<br />
TREATMENT POSTER III<br />
Guselkumab Provides Continued Improvement in Key<br />
Domains of Psoriatic Arthritis Through 2 Years<br />
Laura Coates<br />
Consistent Long-Term Guselkumab Efficacy Across<br />
Psoriatic Arthritis Domains Irrespective of Baseline<br />
Patient Characteristics<br />
Joseph Merola<br />
Serum Extracellular Matrix Biomarkers Identify<br />
Response to Guselkumab in Psoriatic Arthritis; Posthoc<br />
Analysis from a Phase 3, Randomized, Doubleblind,<br />
Placebo-controlled Study Through 2 Years<br />
Signe Holm Nielsen<br />
Minimal Disease Activity Response Patterns in Bio-<br />
Naïve Patients Treated with Guselkumab: A Machine<br />
Learning Analysis<br />
Alen Zabotti<br />
Safety of Deucravacitinib, an Oral, Selective Tyrosine<br />
Kinase 2 Inhibitor: As Assessed by Laboratory<br />
Parameters – Results from a Phase 2 Trial in Psoriatic<br />
Arthritis and 2 Phase 3 Trials in Psoriasis<br />
Roy Fleischmann<br />
Baseline Biomarkers Predict Better Responses to<br />
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2<br />
(TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis<br />
Christopher Ritchlin<br />
Deucravacitinib Long-term Efficacy and Safety in<br />
Plaque Psoriasis: 2-Year Results from the Phase 3<br />
POETYK PSO Program<br />
Richard Warren
Chairman’s Picks<br />
2136<br />
2137<br />
2138<br />
2139<br />
2141<br />
2142<br />
Deucravacitinib, an Oral, Selective Tyrosine Kinase<br />
2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis:<br />
Achievement of Minimal Disease Activity and Its<br />
Components<br />
Arthur Kavanaugh<br />
Impact of Patient Characteristics, Including Sex,<br />
on the Efficacy of Upadacitinib Compared with<br />
Adalimumab in Patients with Psoriatic Arthritis<br />
Lihi Eder<br />
Real-world Persistence and Treatment Patterns in<br />
Psoriatic Arthritis Patients Treated with Anti-IL17<br />
Therapy<br />
Sebastian Moyano<br />
Sustained Response to Guselkumab Regardless of<br />
Baseline Demographic, Disease, and Medication<br />
Characteristics in Patients with Active Psoriatic<br />
Arthritis and an Inadequate Response to TNF<br />
Inhibitors: Results from a Phase 3b Trial<br />
Iain B McInnes<br />
How Well Does Ultrasound-assessed Synovitis<br />
in Reduced Joint Sets Predict the Response to<br />
Secukinumab in Patients with Active Psoriatic Arthritis<br />
and Inadequate Response to Conventional DMARDs?<br />
– Exploratory Results from a Phase 3b Study<br />
Maria-Antonietta D’Agostino<br />
Strong Correlation Between Short- vs Long-form<br />
Composite Measures of Psoriatic Arthritis Disease<br />
Activity in a TNFi-IR Population Treated with<br />
Guselkumab: Data from the Phase 3b COSMOS Trial<br />
William Tillett<br />
2146<br />
2149<br />
2150<br />
2151<br />
09:15–<br />
09:25<br />
L02<br />
Efficacy of Upadacitinib in Patients with Psoriatic<br />
Arthritis and Prior Exposure to Anti-TNF Therapy in<br />
the SELECT-<strong>PsA</strong> 2 Trial Through 2 Years<br />
Philip J Mease<br />
Cycling versus Swapping Strategies in Psoriatic<br />
Arthritis: Results from the Rheumatic Diseases<br />
Portuguese Register<br />
Francisca Guimarães<br />
Cycling vs Swapping Strategies with TNFi and IL-17i<br />
in Psoriatic Arthritis: An Observational Retrospective<br />
Monocentric Study<br />
Carlo Salvarani<br />
Izokibep Demonstrates Clinically Relevant Efficacy<br />
Benefits on Enthesitis, Dactylitis and Nail Outcomes<br />
in Active <strong>PsA</strong> Patients: A 16-week Randomized,<br />
Placebo-controlled Trial<br />
Kurt de Vlam<br />
ORAL SESSION<br />
LATE-BREAKING ABSTRACTS (L01–L06)<br />
Bimekizumab Treatment in Biologic DMARD-Naïve<br />
Patients with Active Psoriatic Arthritis: 52-Week<br />
Efficacy and Safety Results from a Phase 3,<br />
Randomized, Placebo-Controlled, Active Reference<br />
Study<br />
Christopher T. Ritchlin<br />
2143<br />
Effect of Upadacitinib and Adalimumab on Residual<br />
Pain Among Patients with Psoriatic Arthritis Whose<br />
Inflammation Was Attenuated After Three and Six<br />
Months of Treatment<br />
Louis Bessette<br />
2145<br />
Efficacy and Safety of Risankizumab for Active<br />
Psoriatic Arthritis: 100-Week Results from the<br />
KEE<strong>PsA</strong>KE 1 and KEE<strong>PsA</strong>KE 2 Trials<br />
Lars Erik<br />
Register for FREE content at www.cytokinesignalling.com<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE<br />
Follow us at:<br />
Cytokine Signalling Forum
Change language